FIELD: pharmacology.
SUBSTANCE: composition contains pemetrexed or a pharmaceutically acceptable salt thereof as an active ingredient, N-acetyl-L-cysteine and sodium citrate, wherein the concentration ratio is -30 : 0.15 - 2.0 : 1.0 - 15.0, respectively. The liquid composition can be stored in a solution state. The composition is an injectable liquid composition in an airtight container. The composition is ready for use.
EFFECT: combined use of pemetrexed, N-acetyl-L-cysteine and sodium citrate provides a composition that is highly stable and maintained in a clear solution without precipitation during storage.
5 cl, 1 dwg, 12 tbl, 16 ex
Title | Year | Author | Number |
---|---|---|---|
STABILIZED PEMETREXEDE COMPOSITION | 2014 |
|
RU2636783C2 |
STABLE PHARMACEUTICAL COMPOSITION OF 5,10-METHYLENTETRAHYDROFOLATE | 2004 |
|
RU2343923C2 |
PHARMACEUTICAL COMPOSITION CONTAINING PALANOSETRON AS AN ACTIVE INGREDIENT | 2017 |
|
RU2732407C1 |
PHARMACEUTICAL COMPOSITION | 2011 |
|
RU2604690C2 |
STABLE LIQUID ETANERCEPT COMPOSITION | 2012 |
|
RU2575619C2 |
PHARMACEUTICAL COMPOSITION | 2011 |
|
RU2737264C2 |
STABLE FORMULATIONS OF BORTEZOMIB | 2011 |
|
RU2529800C2 |
DOPA DECARBOXYLASE INHIBITOR COMPOSITIONS | 2015 |
|
RU2684105C2 |
STABILISED COMPOSITION CONTAINING AT LEAST ONE ADRENERGIC COMPOUND | 2010 |
|
RU2527337C9 |
PARENTERAL LIQUID PREPARATION INCLUDING CARBAMATE COMPOUND | 2017 |
|
RU2761041C2 |
Authors
Dates
2017-05-24—Published
2013-11-29—Filed